DNTH
Dianthus Therapeutics, Inc.Healthcare·Biotechnology
$93.01
$3.9B market cap
Revenue
$0.8M
Free Cash Flow
$-76.0M
Rev Growth
+0.0%
FCF Margin
-10172.3%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
2-Year Price History
$86.48+300.2%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.5 | -46.5 | -46.5 | -40.8 | -28.9 | -28.9 | -0.0 | 1,111 | 1.4 | 48.0 | -21.5% | -- | -- |
| Act | 2025-Q4 | 0.3 | -69.3 | -69.5 | 97.9 | -47.0 | -47.1 | -0.1 | 404.3 | 1.4 | 37.8 | -172.0% | -- | -- |
Valuation & Metrics
Market Stats
Price$93.01
Market Cap$3.9B
Enterprise Value$2.8B
P/S Ratio5198.4x
P/FCF--
EV/FCF--
FCF Margin (TTM)-10172.3%
FCF Yield-2.0%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.8M
Net Income$57.1M
Free Cash Flow$-76.0M
Revenue Growth (YoY)+0.0%
EBITDA Margin-15504.0%
Net Margin7640.0%
FCF Margin-10172.3%
CapEx % of Revenue19.8%
SBC % of Revenue2219.5%
ROIC-96.7%
WC Change % Rev-758.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares6.6M
Days to Cover14.1
Change (vs Prior)-0.2%
Need at least 2 settlement dates for chart
Employees
Headcount78
Revenue / Employee$9,577
Gross Profit / Employee$8,603
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
117.5%(+101.4% YoY)
223 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
19.6%(+17.6% YoY)
11 filers
Vanguard, iShares, SPDR
Market makers
0.3%(+0.2% YoY)
6 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| FMR LLC | $652M | $36.67 | +$112M | +$276M | -0.0% | $1.89T |
| BlackRock, Inc.Passive | $267M | $50.09 | +$106M | +$131M | -0.2% | $5.69T |
| RA CAPITAL MANAGEMENT, L.P. | $219M | $39.71 | +$83.9M | −$21.4M | -4.6% | $9.44B |
| WELLINGTON MANAGEMENT GROUP LLP | $218M | $40.50 | +$7.8M | +$212M | -0.3% | $533.98B |
| Fairmount Funds Management LLC | $213M | $28.84 | +$33.6M | −$13.7M | +4.0% | $1.38B |
| Avidity Partners Management LP | $177M | $28.34 | +$0 | +$32.2M | -9.1% | $505M |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $170M | $83.92 | +$170M | +$170M | — | $4.04T |
| Octagon Capital Advisors LP | $163M | $23.45 | −$39.4M | −$33.1M | +0.1% | $904M |
| TCG Crossover Management, LLC | $141M | $23.63 | +$0 | +$14.7M | +4.5% | $3.50B |
| CITADEL ADVISORS LLC | $135M | $45.08 | +$45.4M | +$95.6M | -0.4% | $138.22B |
| STATE STREET CORPPassive | $117M | $33.50 | −$9.1M | +$53.6M | -0.2% | $2.89T |
| T. Rowe Price Investment Management, Inc. | $108M | $83.92 | +$108M | +$108M | -1.3% | $145.22B |
| VR Adviser, LLC | $99.0M | $27.84 | +$15.1M | −$47.4M | -2.1% | $2.68B |
| FRED ALGER MANAGEMENT, LLC | $97.5M | $79.96 | +$94.7M | +$97.5M | -0.3% | $22.77B |
| PRICE T ROWE ASSOCIATES INC /MD/ | $96.3M | $60.50 | +$44.6M | +$95.4M | -0.2% | $864.93B |
| Polar Capital Holdings Plc | $90.3M | $42.75 | +$6.0M | +$90.3M | +1.5% | $22.76B |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $85.6M | $83.92 | +$85.6M | +$85.6M | -0.9% | $7.18B |
| FRANKLIN RESOURCES INC | $81.2M | $62.64 | +$42.4M | +$81.2M | -0.2% | $403.03B |
| Cormorant Asset Management, LLC | $79.7M | $83.92 | +$79.7M | +$79.7M | -2.4% | $1.95B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $76.9M | $42.52 | +$20.1M | +$33.5M | +2.3% | $1.61T |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)NEUTRAL
Holders
+0.01%
avg per quarter
Holders (ex-self)
-0.15%
excl. this stock
Buyers (this Q)
+0.23%
175 buyers · $2.82B in
Sellers (this Q)
+0.39%
58 sellers · $-0.22B out
alpha coverage: 96% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+9.0%
how holders react when this stock falls
On quiet Qs
-2.3%
−10% to +10% baseline
On rallies (+10%+)
+13.0%
how they react when this stock rises
Holders' portfolio flow this Q
-0.6%
outflows — trims may be forced
Sellers' portfolio flow this Q
+0.4%
Sellers' overall flow ~ flat.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-6.1%
Holder mid (any stock)
-4.4%
Holder rally (any stock)
-6.7%
Biggest decreases this quarter
Octagon Capital Advisors LP−$39.4Mα+0.1BRAIDWELL LP−$31.4Mα-1.9GREAT POINT PARTNERS LLCexited−$14.4MSTATE STREET CORP−$9.1Mα-0.2SILVERARC CAPITAL MANAGEMENT, LLC−$8.0Mα-0.5PUBLIC SECTOR PENSION INVESTMENT BOARDexited−$2.0MTWO SIGMA INVESTMENTS, LPexited−$2.0MJANE STREET GROUP, LLCexited−$1.9MVOLORIDGE INVESTMENT MANAGEMENT, LLCexited−$1.6MRENAISSANCE TECHNOLOGIES LLCexited−$1.3M
New buyers this quarter
Top-5 holders · 30.3%
FMR LLC--
BlackRock, Inc.--
RA CAPITAL MANAGEMENT, L.P.--
WELLINGTON MANAGEMENT GROUP LLP--
Fairmount Funds Management LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
FMR LLC7.8MRA CAPITAL MANAGEMENT, L.P.2.6MWELLINGTON MANAGEMENT GROUP LLP2.6MFairmount Funds Management LLC2.5MAvidity Partners Management LP2.1MOctagon Capital Advisors LP1.9MTCG Crossover Management, LLC1.7MCITADEL ADVISORS LLC1.6MT. Rowe Price Investment Management, Inc.1.3MVR Adviser, LLC1.2M
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| CNTX | Context Therapeutics Inc. | 3 | 147.05× |
| RAPP | Rapport Therapeutics, Inc. Common Stock | 3 | 122.54× |
| AKTS | Aktis Oncology, Inc. | 3 | 105.03× |
| ELVN | Enliven Therapeutics, Inc. | 7 | 100.91× |
| SVRA | Savara Inc. | 4 | 98.03× |
| NUVL | Nuvalent, Inc. | 6 | 98.03× |
| CNTA | Centessa Pharmaceuticals plc | 10 | 98.03× |
| ERAS | Erasca, Inc. | 7 | 95.31× |
| TRVI | Trevi Therapeutics, Inc. | 4 | 89.12× |
| DMRA | Galecto, Inc. | 3 | 81.69× |
| PVLA | Palvella Therapeutics, Inc. | 3 | 81.69× |
| GLUE | Monte Rosa Therapeutics, Inc. | 3 | 81.69× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (10 analysts)$117.602640.0%
Last Year (17 analysts)$99.29680.0%
Current Price$93.01
Analyst Ratings
1
9
Strong Buy: 1Buy: 9Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$37.80M
12 txns · 5 insiders · 588,351 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-08 | SELL | Soteropoulos Paula | director | 599 | $85.47 | $51K | $0 |
| 2026-04-09 | SELL | Savitz Ryan | officer: EVP, CFO & CBO | 8,224 | $89.84 | $739K | $0 |
| 2026-03-31 | SELL | Savitz Ryan | officer: EVP, CFO & CBO | 114,367 | $83.00 | $9.49M | $0 |
| 2026-03-31 | SELL | Soteropoulos Paula | director | 599 | $80.11 | $48K | $0 |
| 2026-03-24 | SELL | Soteropoulos Paula | director | 27,594 | $78.05 | $2.15M | $0 |
| 2026-03-12 | SELL | CARR EDWARD | officer: CHIEF ACCOUNTING OFFICER | 43,682 | $81.49 | $3.56M | $0 |
| 2026-03-12 | SELL | Garcia Marino | director, officer: CEO AND PRESIDENT | 122,918 | $81.49 | $10.02M | $0 |
| 2026-03-12 | SELL | Randhawa Simrat | officer: EVP, Head of R&D | 33,830 | $81.48 | $2.76M | $0 |
| 2025-12-04 | SELL | Savitz Ryan | officer: CFO & CBO | 20,000 | $45.18 | $904K | $0 |
| 2025-11-14 | SELL | Randhawa Simrat | officer: EVP, Head of R&D | 109,031 | $38.14 | $4.16M | $153K |
| 2025-11-13 | SELL | Randhawa Simrat | officer: EVP, Head of R&D | 87,507 | $36.81 | $3.22M | $147K |
| 2025-09-09 | SELL | Savitz Ryan | officer: CFO & CBO | 20,000 | $35.00 | $700K | $0 |
Order Flow (FINRA, ~3w lag)
7.3%retail+1.3pp
36.8%dark-0.3pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Dianthus Therapeutics (DNTH): Accelerating Burn and Coordinated Insider Exit Plans
Overall Risk
7/10
Fraud
3/10
Dilution
8/10
Insolvency
4/10
Earnings Overstated
2/10
Hidden Liabilities
5/10
Legal
3/10
Audit Warnings
4/10
Hidden Upside
6/10
Contextually Acceptable
6/10